Next Article in Journal
Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers
Next Article in Special Issue
Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil
Previous Article in Journal
Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases
Previous Article in Special Issue
Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation
 
 
Article

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors

1
Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
2
Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 11528 Athens, Greece
*
Author to whom correspondence should be addressed.
Academic Editors: Steven B. Bradfute, Ralph A. Tripp and Scott Anthony
Vaccines 2021, 9(10), 1148; https://doi.org/10.3390/vaccines9101148
Received: 2 September 2021 / Revised: 2 October 2021 / Accepted: 4 October 2021 / Published: 8 October 2021
(This article belongs to the Collection COVID-19 Vaccines and Vaccination)
Objective: Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy. Methods: In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti-SARS-CoV-2 antibodies (NAbs) after COVID-19 vaccination. Baseline demographics, co-morbidities, and NAb levels were compared between the two groups. Results: The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS-CoV-2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose. Conclusions: These results suggest that maintaining precautions against COVID-19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment. View Full-Text
Keywords: ovarian cancer; SARS-CoV-2; vaccination; PARP inhibitors ovarian cancer; SARS-CoV-2; vaccination; PARP inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Liontos, M.; Terpos, E.; Markellos, C.; Zagouri, F.; Briasoulis, A.; Katsiana, I.; Skafida, E.; Fiste, O.; Kunadis, E.; Andrikopoulou, A.; Kaparelou, M.; Koutsoukos, K.; Gavriatopoulou, M.; Kastritis, E.; Trougakos, I.P.; Dimopoulos, M.-A. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. Vaccines 2021, 9, 1148. https://doi.org/10.3390/vaccines9101148

AMA Style

Liontos M, Terpos E, Markellos C, Zagouri F, Briasoulis A, Katsiana I, Skafida E, Fiste O, Kunadis E, Andrikopoulou A, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos M-A. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. Vaccines. 2021; 9(10):1148. https://doi.org/10.3390/vaccines9101148

Chicago/Turabian Style

Liontos, Michalis, Evangelos Terpos, Christos Markellos, Flora Zagouri, Alexandros Briasoulis, Ioanna Katsiana, Efthymia Skafida, Oraianthi Fiste, Elena Kunadis, Angeliki Andrikopoulou, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P. Trougakos, and Meletios-Athanasios Dimopoulos. 2021. "Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors" Vaccines 9, no. 10: 1148. https://doi.org/10.3390/vaccines9101148

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop